The abortion pill should not be assumed to be safe simply because it is widely used. After the Supreme Court overturned Roe v. Wade, states regained the authority to regulate abortion, including abortion pills, which now account for roughly 50% of all abortions. As restrictions returned, claims about the pill’s safety came under renewed scrutiny.
Reported outcomes challenge the idea that abortion pills are low-risk. Over their first 16 years of use, abortion pills were associated with 24 deaths and more than 4,000 adverse events. The complication rate for abortion pills is reported to be four times higher than that of first-trimester surgical abortions. These risks existed even when stricter safety protocols were in place.
Despite this, the FDA removed long-standing safeguards, including the requirement for in-person doctor visits before prescribing abortion pills. In response, a group of pro-life doctors has petitioned the Supreme Court to restore those protections, arguing that removing them exposes women to greater medical danger. At the same time, some abortion-pill advocates have openly expressed frustration with legal limits and suggested they will not comply with them.
This raises both medical and legal concerns. A long-standing federal law prohibits mailing abortion drugs, meaning those who bypass regulations may be exposing themselves and others to serious legal risk. Expanding access while reducing oversight shifts the burden of harm away from regulators and onto women who experience complications.
Key Takeaways
A drug associated with deaths and thousands of adverse events should not be labeled “safe” simply because it is common.
A higher complication rate than surgical abortion undermines claims that abortion pills are the safer option for women.
Removing in-person medical oversight increases the likelihood of unmanaged complications, coercion, and misuse.
Encouraging or tolerating illegal distribution places women at medical and legal risk while avoiding accountability for harm.